SMTL ID : 6iwi.1

Crystal structure of PDE5A in complex with a novel inhibitor

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.15 Å

Oligo State

monomer

Ligands

1 x MG: MAGNESIUM ION(Non-covalent)

MG.1: 2 residues within 4Å: Chain A: D.141, E.169 5 PLIP interactions: 1 interactions with chain A, 4 Ligand-Water interactions Metal complexes: A:D.141, H2O.1, H2O.1, H2O.2, H2O.3

1 x ZN: ZINC ION(Non-covalent)

ZN.2: 4 residues within 4Å: Chain A: H.104, H.140, D.141, D.251 6 PLIP interactions: 4 interactions with chain A, 2 Ligand-Water interactions Metal complexes: A:H.104, A:H.140, A:D.141, A:D.251, H2O.2, H2O.3

1 x B0C: N-[3-(4,5-diethyl-6-oxo-1,6-dihydropyrimidin-2-yl)-4-propoxyphenyl]-2-(4-methylpiperazin-1-yl)acetamide(Non-covalent)

B0C.3: 10 residues within 4Å: Chain A: Y.99, L.252, A.266, V.269, F.273, M.303, Q.304, G.306, F.307, A.310 10 PLIP interactions: 10 interactions with chain A Hydrophobic interactions: A:V.269, A:M.303, A:F.307, A:F.307, A:F.307 Hydrogen bonds: A:Q.304, A:Q.304 Water bridges: A:M.303, A:F.307 pi-Stacking: A:F.307

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Wang, Z. et al., Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension. J.Med.Chem. (2019)

Release Date

2019-12-11

Peptides

cGMP-specific 3',5'-cyclic phosphodiesterase: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

cGMP-specific 3',5'-cyclic phosphodiesterase

Related Entries With Identical Sequence